- 85 million euros invested in the new Solids Launch facility in Ingelheim
- 75 employees to develop and manufacture tablet drugs starting in 2020
- Production of older drugs relocated since 2016 to focus on complex chemical production
- Previous 34 million euro diabetes facility to relocate production to Mexico and Greece by 2020
Investment and Focus
Boehringer Ingelheim is investing 85 million euros in a new Solids Launch facility in Ingelheim, Germany. This facility will focus on developing and manufacturing innovative tablet drugs for global market launches, emphasizing modern and flexible production methods.
Employee and Production Shifts
Starting in 2020, 75 employees will work on new production methods for tablet preparations, centralizing manufacturing for worldwide launches. Since 2016, the production of older, easier-to-manufacture drugs has been relocated to other countries, allowing the company to concentrate on more complex chemical production tasks.
Regional Impact
Malu Dreyer, Minister President of Rhineland-Palatinate, highlighted the importance of future-oriented technologies and the value they add to the region. The state supports companies with measures to ensure specialist staff and initiatives to engage young people in STEM fields.
Previous Investments
Between 2016 and 2017, Boehringer Ingelheim built a 34 million euro facility in Ingelheim for innovative antidiabetic agents. By 2020, production from this facility will be relocated to countries like Mexico and Greece, aligning with the company's strategy to maintain flexibility and respond to market changes.
